ASCO 2014 – Where the Tumors Are Located Influences Survival

ASCO has become a little more interesting for prostate cancer. Today's item is about a mega-analysis that confirms that the site of metastatic tumors will  powerfully predict overall survival (OS) among men with metastatic castration resistant prostate cancer (mCRPC). Older and smaller studies had previously suggested that the metastatic site is prognostic for OS.  This [...]

Using Circulating Tumor Cells as a Prognostic Tool – Better than PSA

Better prediction tools to predict treatment outcome in men with metastatic castration-resistant prostate cancer (mCRPC) should significantly improve treatment outcomes. Without good predictive measures we often don't know when is the optimum time to stop a therapy and move to another. This means that we might maturely stop an effective treatment losing the effectiveness of [...]

A Take Away Point from the Last American Urological Association (AUA) Meeting

The prognosis of patients with advanced prostate cancer who have lymph node metastasis depends on the number of positive lymph nodes removed and Gleason score of the primary tumor. Bilateral pelvic lymph node dissection should be performed in intermediate- and high-risk patients to identify those with minimal nodal burden who may benefit the most from [...]